Mersana Therapeutics, Inc. CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and ...
CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...
CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...
This page features the latest news about the Mersana Therapeutics stock. MRSN stock touches 52-week low at $0.56 amid market challenges Mersana Therapeutics Inc . (NASDAQ:MRSN) stock has reached a ...
Bala Mohan, the Senior Vice President and Chief Development Officer at Mersana Therapeutics, Inc. (NASDAQ:MRSN), recently sold shares of the company as per a filing with the Securities and ...
Hosted on MSN29d
Mersana therapeutics VP Mandelia sells $1,128 in stockCAMBRIDGE, MA—Mersana Therapeutics, Inc. (NASDAQ:MRSN) recently reported that Ashish Mandelia, the company's Vice President and Chief Accounting Officer, executed a sale of common stock.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback